Navigation Links
ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
Date:6/2/2009

*Improving budgeting and forecasting accuracy
*IT considerations, including interactive voice response, electronic data capture, and upfront database design
*Impact of adaptive trial designs on drug supply

Blake-Michaels brings more than 20 years of clinical operations experience to the DIA session, with extensive experience in the strategic planning and execution of clinical development programs across a wide variety of therapeutic areas. Before joining ClearTrial, she worked for pharmaceutical companies such as Abbott Labs, Fujisawa, TAP, Hospira, and Ovation, as well as one of the largest clinical research organizations. Blake-Michaels has authored over 50 clinical study protocols that included adaptive studies, several investigator brochures and FDA briefing books, and multiple NDA summary documents. As an independent clinical research consultant, she prepared clients for FDA Advisory Committee meetings and post-acquisition portfolio reviews, and planned and managed numerous studies, including a REMS-required patient registry.

About ClearTrial®
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company's software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentio
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
2. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
3. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
4. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
5. Matt Bars, a Global Expert in Smoking Cessation, Joins Next Safety as Chairman
6. Vasogen Appoints Dr. Eldon Smith Chairman
7. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
8. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
9. Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
10. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
11. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
(Date:6/18/2013)... Phoenix, AZ (PRWEB) June 18, 2013 ... the 2013 Innovation Challenge Winner out of hundreds of ... in its spring Arizona Innovation Challenge . The ... the country for a technology commercialization challenge, granting a ... world’s most promising technology ventures. Nasseo’s state of the ...
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
(Date:6/18/2013)... , June 18, 2013 ... has announced the addition of the report ... Companies " to their offering. ... briefly reviews basics of human genome variations, ... Current large and small sequencers are described ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... Cardium Therapeutics (NYSE Amex: CXM ) today ... the U.S. Food and Drug Administration (FDA) seeking marketing ... Excellagen XL is an advanced wound care management ... designed for use by physicians in patients with topical ...
... DUBLIN, Ireland, November 2 The Board of,Directors of ... Mr David,Stout joined the Board as a Non Executive Director ... Mr Stout has extensive pharmaceutical experience. Most recently he was,President, ... pharmaceutical operations in the United States, Europe,Japan and all other ...
... successful phase III trial points to the first new lupus ... 2 The Lupus Research Institute (LRI) and its National ... Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - ... the first successfully tested new drug developed specifically for people ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4New Shire Board Member 2Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus 2
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
(Date:6/17/2013)... The AGA Research Foundation and Horizon Pharma further ... gastroenterology with the 2013 AGA-Horizon Pharma Fellow Abstract Prizes ... "In its third year, this competition continues to grow ... promising careers in basic and clinical research," said Nicholas ... Foundation. "We are extremely proud of all that these ...
(Date:6/16/2013)... programs for female sex workers in India reduce rates ... a University of Toronto study has found. ... mostly in the southern states of Andhra Pradesh, Karnataka, ... Prabhat Jha from U of T,s Dalla Lana School ... Global Health Research (CGHR), examined the impact of prevention ...
Breaking Biology News(10 mins):'Chemical architects' build materials with potential applications in drug delivery and gas storage 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... and the environment will gather in Nairobi, Kenya this ... cycle of drought and food insecurity. The Beating Famine ... the Sahel region of Africa, this time through Niger, ... will take place on April 10-13 at the World ...
... 2012 The Canadian Journal of Cardiology ... Society,s atrial fibrillation guidelines. Atrial fibrillation is the ... stroke, illness in general, and death. It is, for example, ... year has seen important changes in the drugs available to ...
... known for its role in embryonic development and cancer ... or scleroderma, therapy. The finding, discovered by a cross-disciplinary ... Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg ... Arthritis & Rheumatism. "We showed, for ...
Cached Biology News:Beating famine: Sustainable food security through land regeneration in a changing climate 2New genetic path for scleroderma 2
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: